Compare NRIM & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NRIM | NMRA |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 544.8M | 554.0M |
| IPO Year | 2002 | 2023 |
| Metric | NRIM | NMRA |
|---|---|---|
| Price | $27.96 | $1.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 130.2K | ★ 3.4M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $255,581,000.00 | N/A |
| Revenue This Year | $4.98 | N/A |
| Revenue Next Year | $7.40 | N/A |
| P/E Ratio | $44.67 | ★ N/A |
| Revenue Growth | ★ 30.43 | N/A |
| 52 Week Low | $19.60 | $0.72 |
| 52 Week High | $99.18 | $3.65 |
| Indicator | NRIM | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 72.65 | 47.19 |
| Support Level | $26.26 | $0.83 |
| Resistance Level | $28.10 | $2.08 |
| Average True Range (ATR) | 0.81 | 0.20 |
| MACD | 0.23 | 0.02 |
| Stochastic Oscillator | 88.85 | 74.25 |
Northrim BanCorp Inc is a bank holding company operating through three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. The Community Banking segment, which generates the majority of revenue, provides loan and deposit products to business and consumer customers in its market areas. The Home Mortgage Lending segment focuses on the origination and sale of mortgage loans for one-to-four family residential properties, mortgage loan servicing for certain loans sold, and investment in selected residential mortgage loans. The Specialty Finance segment provides factoring, asset-based lending, and alternative working capital solutions to small and medium-sized enterprises and includes SCF and Northrim Funding Services.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.